Scientific Zambon Pharma April 21, 2022 Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
Scientific Zambon Pharma February 21, 2022 COVID-19. A probiotic formula reduces symptom duration and viral load, increases antibodies, and improves remission rate among patients with mild symptoms
Scientific Zambon Pharma September 8, 2021 Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
Scientific Zambon Pharma May 12, 2021 Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson’s disease patient
Scientific Zambon Pharma April 12, 2021 On the World Parkinson’s Day, Zambon announces Synapses study’s results on Parkinson’s patients in real special settings
Institutional ZCube December 21, 2020 HEALTHCARE AND INNOVATION: UP TO €100,000 TO THE STARTUP THAT ADDRESSES WOMEN’S HEALTH ISSUES
Scientific Zambon Pharma November 19, 2020 The importance of protecting the lungs from oxidative stress for COPD patients
Scientific Zambon Pharma September 14, 2020 Zambon announces its Symposium at MDS Virtual Congress 2020: Challenges in the management of Parkinson’s Disease patients during COVID-19 pandemic: What can we expect?
